The Woven EndoBridge Device for the Treatment of Intracranial Aneurysms: Initial Clinical Experience within an Australian Population.

2022-03

Gajera, Jay

Maingard, Julian

Foo, Michelle

Ren, Yifan

Lamanna, Anthony

Nour, Daniel

Hall, Jonathan

Kurda, Dylan

Tan, David

Lalloo, Shivendra

Bañez, Ramon Martin Francisco

Russell, Jeremy H

Slater, Lee-Anne

Chandra, Ronil Vikesh

Chong, Winston

Jhamb, Ashu

Brooks, Duncan Mark

Asadi, Hamed

Endovascular procedures

Flow diversion

Intracranial aneurysm

Intrasaccular

WEB

Woven EndoBridge device

Journal Article

0000-0001-8958-2411

0000-0001-8056-1163

0000-0001-6518-6828

0000-0003-0705-2252

0000-0001-5034-570X

0000-0003-3692-120X

0000-0003-2475-9727

10.5469/neuroint.2021.00430

Advances in endovascular technology have expanded the treatment options for intracranial aneurysms. Intrasaccular flow diversion is a relatively new technique that aims to disrupt blood inflow at the neck of the aneurysm, hence promoting intrasaccular thrombosis. The Woven EndoBridge device (WEB; MicroVention, Aliso Viejo, CA, USA) is an US Food and Drug Administration approved intrasaccular flow diverter for wide-necked aneurysms. We report the early interim clinical and radiological outcomes of patients with both ruptured and unruptured intracranial aneurysms (IAs) treated using the WEB device in an Australian population. A retrospective analysis was done of patients with ruptured or unruptured IAs who received treatment with WEB across 5 Australian neuroendovascular referral centers between May 2017 and November 2020. Angiographic occlusion was assessed with time-of-flight magnetic resonance angiography. Complications were recorded and clinical outcomes were assessed using the modified Rankin scale at follow-up. In total, 66 aneurysms were treated in 63 patients, with successful deployment of the WEB device in 98.5% (n=65). Eighteen (26.9%) ruptured aneurysms were included. Failure of deployment occurred in a single case. Adjunct coiling and/or stenting was performed in 20.9% (n=14) cases. Sixty-two patients with 65 aneurysms using a WEB device were followed up (mean=9.1 months), and 89.4% of these had complete aneurysm occlusion while 1.5% remained patent. Functional independence was achieved in 93.5% of cases. Early results following the use of WEB devices in Australia demonstrate safety and adequate aneurysm occlusion comparable to international literature.

link

Neurointervention 2022; 17(1): 28-36.

Neurointervention

2093-9043